CORK, Ireland, November 27 (HSMN NewsFeed) — The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA® (darunavir) with low-dose ritonavir as part of combination t…
Biopharmaceuticals, HIV/AIDS, Regulatory
Tibotec Pharmaceuticals, Janssen-Cilag, PREZISTA, darunavir

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1”
Leave a Comment